FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Jagpal Sukhi 2. Issuer Name and Ticker or Trading Symbol Sierra Oncology, Inc. [ SRRA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)
C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110
3. Date of Earliest Transaction (MM/DD/YYYY)
7/1/2022
(Street)
SAN MATEO, CA 94404
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $122.20  7/1/2022    D        3859    (1) 3/18/2025  Common Stock  3859  $0.00 (2) 0  D   
Stock Option (right to buy)  $263.20  7/1/2022    D        1218    (3) 3/8/2026  Common Stock  1218  $0.00 (2) 0  D   
Stock Option (right to buy)  $72.80  7/1/2022    D        4200    (4) 9/30/2026  Common Stock  4200  $0.00 (2) 0  D   
Stock Option (right to buy)  $58.00  7/1/2022    D        1750    (5) 3/6/2027  Common Stock  1750  $0.00 (2) 0  D   
Stock Option (right to buy)  $94.40  7/1/2022    D        4509    (6) 3/6/2028  Common Stock  4509  $0.00 (2) 0  D   
Stock Option (right to buy)  $78.40  7/1/2022    D        5000    (7) 3/4/2029  Common Stock  5000  $0.00 (2) 0  D   
Stock Option (right to buy)  $13.31  7/1/2022    D        94113    (8) 2/25/2030  Common Stock  94113  $0.00 (9) 0  D   
Stock Option (right to buy)  $12.15  7/1/2022    D        49000    (10) 8/12/2030  Common Stock  49000  $0.00 (9) 0  D   
Stock Option (right to buy)  $12.15  7/1/2022    D        5887    (11) 8/12/2030  Common Stock  5887  $0.00 (9) 0  D   
Stock Option (right to buy)  $16.73  7/1/2022    D        30000    (12) 3/15/2031  Common Stock  30000  $0.00 (9) 0  D   
Stock Option (right to buy)  $31.54  7/1/2022    D        50000    (13) 3/14/2032  Common Stock  50000  $0.00 (9) 0  D   

Explanation of Responses:
(1)  The option fully vested on February 2, 2019.
(2)  Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
(3)  The option fully vested on January 1, 2020.
(4)  The option fully vested on September 30, 2019.
(5)  The option fully vested on January 1, 2021.
(6)  The option fully vested on January 1, 2022.
(7)  The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
(8)  The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
(9)  Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
(10)  On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
(11)  The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
(12)  The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
(13)  The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Jagpal Sukhi
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO, CA 94404


Chief Financial Officer

Signatures
/s/ Mary Christina Thomson, Attorney-In-Fact for Sukhi Jagpal 7/1/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Sierra Oncology Charts.
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Sierra Oncology Charts.